Dan-Arin Silasi, MD

Associate Professor of Obstetrics, Gynecology, and Reproductive Sciences; Director, 'Discovery to Cure' International Fellowship Program in Gynecologic Oncology; Director, Obesity Robotic Pelvic Surgery Program

Clinical Interests

  • Antineoplastic Combined Chemotherapy Protocols
  • Pelvic Exenteration
  • Pelvic Neoplasms
  • Chemotherapy, Cancer, Regional Perfusion
  • Laparoscopy
  • Precancerous Conditions
  • Gynecologic Surgical Procedures
  • Chemotherapy, Adjuvant
  • Neoadjuvant Therapy
  • Robotic Surgical Procedures
  • Cytoreduction Surgical Procedures

Patient Care

Accepts new patients? Yes
Patient Type: Adult; Adolescent; Child; Geriatric
Referrals: From patients or physicians

Patient Care Organizations

Obstetrics, Gynecology & Reproductive Sciences: Discovery to Cure | Gynecologic Oncology Program: Ovarian Cancer Early Detection Program | Women's Reproductive Cancers Program

Yale Cancer Center: Gynecologic Oncology Program: Ovarian Cancer Early Detection Program

Yale Medicine

Office of Cooperative Research

Board Certifications

  • Obstetrics & Gynecology AB of Obstetrics & Gynecology (2010)

  • Gynecologic Oncology AB of Obstetrics & Gynecology (2012)

Clinical Trials

Conditions Study Title
Other Female Genital, Ovary Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects With Different HRD Tumor Status and With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 2 Prior Lines of Chemotherapy
Ovary A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Ovary An Open-label Phase Ib Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Maximum Tolerated Dose of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin 30 mg/m2 Given Every 3 Weeks in Subjects With Mesothelin-expressing Platinum-resistant Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Corpus Uteri A phase II evaluation of pembrolizumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent hypermutated/ultramutated endometrial cancer identified by next generation sequencing (NGS) and comprehensive genomic profiling (CGP), A Pilot Study
Anus, Bladder, Bones and Joints, Brain and Nervous System, Breast - Female, Breast - Male, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Hodgkin's Lymphoma, Kaposi's sarcoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Lymphoid Leukemia, Melanoma, skin, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Cervix Uteri Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) Using a Novel "Prime and Pull" Strategy
Ovary Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Edit this profile

Contact Info

Dan-Arin Silasi, MD
Patient Care Locations
Yale Gynecologic OncologySmilow Cancer Hospital at Yale New Haven
35 Park Street, Ste 1st floor

New Haven, CT 06511
View on map...
Yale Gynecologic OncologyStamford Hospital
1 Hospital Plaza

Stamford, CT 06902
View on map...
Mailing Address
Obstetrics, Gynecology & Reproductive SciencesPO Box 208063
New Haven, CT 06520-8063